EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

被引:2086
|
作者
Singh, A. [1 ]
Settleman, J. [1 ]
机构
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Canc Ctr, Charlestown, MA 02129 USA
关键词
EMT; cancer; cancer stem cells; drug resistance; EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION SIGNATURE; TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; MIR-200; FAMILY; E-CADHERIN; LUNG-CANCER; REPRESSORS ZEB1; SMAD PROTEINS;
D O I
10.1038/onc.2010.215
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumors are cellularly and molecularly heterogeneous, with subsets of undifferentiated cancer cells exhibiting stem cell-like features (CSCs). Epithelial to mesenchymal transitions (EMT) are transdifferentiation programs that are required for tissue morphogenesis during embryonic development. The EMT process can be regulated by a diverse array of cytokines and growth factors, such as transforming growth factor (TGF)-beta, whose activities are dysregulated during malignant tumor progression. Thus, EMT induction in cancer cells results in the acquisition of invasive and metastatic properties. Recent reports indicate that the emergence of CSCs occurs in part as a result of EMT, for example, through cues from tumor stromal components. Recent evidence now indicates that EMT of tumor cells not only causes increased metastasis, but also contributes to drug resistance. In this review, we will provide potential mechanistic explanations for the association between EMT induction and the emergence of CSCs. We will also highlight recent studies implicating the function of TGF-beta-regulated noncoding RNAs in driving EMT and promoting CSC self-renewal. Finally we will discuss how EMT and CSCs may contribute to drug resistance, as well as therapeutic strategies to overcome this clinically. Oncogene (2010) 29, 4741-4751; doi: 10.1038/onc.2010.215; published online 7 June 2010
引用
收藏
页码:4741 / 4751
页数:11
相关论文
共 50 条
  • [31] Heterogeneity of cancer stem cells in drug resistance and metastasis
    Gotoh, Noriko
    CANCER SCIENCE, 2025, 116 : 182 - 182
  • [32] Approaches for targeting cancer stem cells drug resistance
    Rosa, Roberta
    D'Amato, Valentina
    De Placido, Sabino
    Bianco, Roberto
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (12) : 1201 - 1212
  • [33] Ovarian cancer stem cells and their role in drug resistance
    Pieterse, Zalitha
    Amaya-Padilla, Monica Angelica
    Singomat, Terence
    Binju, Mudra
    Madjid, Bau Dilam
    Yu, Yu
    Kaur, Pritinder
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2019, 106 : 117 - 126
  • [34] Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
    Garg, Pankaj
    Malhotra, Jyoti
    Kulkarni, Prakash
    Horne, David
    Salgia, Ravi
    Singhal, Sharad S.
    CANCERS, 2024, 16 (13)
  • [35] Linking EMT to ovarian cancer stem cells
    Strauss, Robert
    Li, ZongYi
    Liu, Ying
    Sova, Pavel
    Drescher, Charles
    Urban, Nicole
    Lieber, Andre
    CANCER RESEARCH, 2008, 68 (09)
  • [36] On the connections between cancer stem cells and EMT
    Cioce, Mario
    Ciliberto, Gennaro
    CELL CYCLE, 2012, 11 (23) : 4301 - 4301
  • [37] Inflammation linking EMT and cancer stem cells
    Zhou, Chenchen
    Liu, Jeffrey
    Tang, Yaling
    Liang, Xinhua
    ORAL ONCOLOGY, 2012, 48 (11) : 1068 - 1075
  • [38] Metastasis: EMT, microRNAs and cancer stem cells
    Brabletz, Thomas
    CLINICAL & EXPERIMENTAL METASTASIS, 2015, 32 (03) : 187 - 187
  • [39] Stem cells, melanoma and cancer stem cells: the good, the bad and the evil?
    Menaa, F.
    Houben, R.
    Eyrich, M.
    Broecker, E. B.
    Becker, J. C.
    Wischhusen, J.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (03): : 287 - 296
  • [40] Resveratrol: Targeting Cancer Stem Cells and ncRNAs to Overcome Cancer Drug Resistance
    Rezakhani, Leila
    Salmani, Sima
    Dashtaki, Masoumeh Eliyasi
    Ghasemi, Sorayya
    CURRENT MOLECULAR MEDICINE, 2024, 24 (08) : 951 - 961